Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04887506
Title TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Tavanta Therapeutics

prostate adenocarcinoma


Abiraterone + Prednisone

Prednisone + TAVT-45

Age Groups: senior | adult
Covered Countries USA | FRA | ESP

No variant requirements are available.